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One of the characteristics of systemic lupus erythema-
tosus (SLE) is the large inter- and intra-individual
variability of the clinical course. Lupus nephritis is no
exception. Some patients with kidney involvement may
show rapid progression to renal failure, while others
may enter complete and stable remission after ade-
quate therapy. More difficult to manage are the large
number of patients who have similar clinical and
histological patterns at presentation, but alternate
periods of clinical quiescence with renal relapses of
different severity. It is still uncertain which, if any,
immunologic parameters may help to diagnose a renal
flare. The increase in anti double-stranded DNA
(dsDNA) titre or hypocomplementaemia related to
classical pathway activation provides no indication as
to whether a relapse includes the kidney. Here we
review the evidence, which has accumulated over the
last few years and appears to indicate that antiC1q
autoantibodies (antiC1q Ab) may help in distingui-
shing a renal from a non-renal relapse under certain
circumstances.
Classical pathway of complement activation
C1q, the first component of the classical pathway of
complement activation, contains six distinct globular
heads and a unique collagen-like region. Several
functions have been assigned to C1q. They include
principally the initial step of complement activation by
the binding of the globular heads of the C1q molecule
to the Fc portions of immune complexes and the
participation in the clearance of self antigens generated
during programmed cell death [1,2]. Autoantibodies to
C1q were first identified in the serum of patients with
SLE, as ‘C1q precipitins’ [3]. A more detailed analysis
followed over the years, and it is now well established
that antiC1q Ab are mostly of the IgG isotype and the
epitopes recognized are on the collagen-like region
(CLR) of C1q [4]. IgG antibodies to CLRuC1q were
quantitated in serum by ELISA, using purified human
CLR or whole C1q as antigen and they provide almost
identical results [5,6]. Studies of the prevalence of IgG
antibodies to CLRuC1q have reported low frequencies
in normal healthy donors (3–5%); however, there is an
increase with age [7]. Several reports have indicated
that 30–50% of sera from patients with SLE contain
antibodies of the IgG isotype reactive with human C1q
[4,8–10]. Interestingly, antiC1q Ab have also been
found in a small group of patients presenting a disease
profile close to SLE, but having as the main clinical
sign urticaria [hypocomplementaemic urticaria vascu-
litis syndrome (HUVS)] [11,12]. The prevalence of
antiC1q Ab is increased in some other autoimmune
diseases, so that they are unlikely to be of help in the
diagnosis of SLE, except perhaps when they suggest
under the appropriate circumstances HUVS.
SLE and antiC1q antibodies
In SLE, antiC1q Ab have been found to be associated
with low complement and lupus nephritis, but not with
a general score of disease activity [4,13]. Although
there is no evidence that antiC1q Ab can directly
activate complement in a normal serum, these Ab are
somehow linked to complement activation in vivo since
they best correlate with a low C1q [14]. The second
association is more directly of clinical interest: almost
all patients reported to have a severe lupus nephritis
(WHO IIIuIV) or a relapse of nephritis had antiC1q Ab
at the time of the renal involvement [10,15–17]. This
finding does not stem from one report only, but
appears to be a general finding in many studies that
have addressed this point. In addition, clinical signs of
renal involvement were found to be associated with
significantly increased serum titres of anti C1q Ab in
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the 6 months preceding the renal relapse [18].
Interestingly, when compared with antiC1q Ab, an
increase in the anti dsDNA level was associated with
all forms of relapses in SLE patients but did not single
out the renal relapses [19]. Recently, Trendelenburg
et al. [20] presented direct evidence for a lack of
occurrence of severe lupus nephritis among antiC1q
antibody negative patients. None of the patients who
were negative for antiC1q antibodies had or developed
active nephritis. These data should however be put into
perspective. Gunnarsson et al. [21] have recently
reported that only 11 out of 18 patients with biopsy-
proven lupus nephritis had antiC1q Ab. However, they
reported simultaneously that C1q was low in most of
these patients and correlated inversely with antiC1q
Ab (P-0.0009), suggesting the presence of antiC1q
below the detection limit. In fact the same group had
reported that in all of six patients with proliferative
lupus nephritis they could find peripheral B-cell
producing specific antiC1q Ab, but did not find such
Ab in the serum of all six patients [22]. This illustrates
that standardization of the antiC1q Ab assay is
required. For instance, in another report, a result for
antiC1q Ab was reported as positive only when it
exceeded the normal range q5 standard deviations
(SD) as compared with the usual 2 SD [23]. This
emphasizes an important aspect, which is that from a
clinical point of view only the absence of antiC1q Ab
may have an impact for the management of the
patients. Since recurrence of lupus nephritis is highly
unlikely in the absence of these antibodies, aggressive
treatment can be tailored accordingly. Thus, a regular
follow-up of antiC1q Ab could be proposed. A word
of caution comes from isolated reports of no antiC1q
Ab in patients with pure membranous glomerulo-
nephritis (WHO V) or with an anticardiolipin syn-
drome associated with major renal damage. Thus, the
presence of antiC1q might be a component of lupus
nephritis excluding membranous nephritis (WHO V)
and other renal lesions, which might occur during the
progression of the disease. On a pathophysiological
basis we may speculate that antiC1q Ab are necessary,
but not sufficient, for producing the immune damage
in the glomeruli since many individuals with SLE or
HUVS have high titres but no renal involvement on a
clinical basis. Interestingly, lupus nephritis is charac-
terized by the deposition of C1q along glomerular and
tubular basement membranes [24] and Mannik and
Wener [25] showed that antiC1q are to be found in
the same deposits. Figure 1 shows the characteristic
C1q distribution in a renal biopsy studied by direct
immunofluorescence in a patient with class V (WHO
classification) glomerulonephritis, which is identical to
IgG deposition. The sum of these observations would
suggest that C1q and the antiC1q autoAb are one of
the central elements in severe lupus nephritis.
Ideally, the diagnosis of renal flares should be based
on kidney biopsy, but because of its potential compli-
cations, this invasive procedure cannot be repeated too
frequently. Thus the monitoring of antiC1q Ab after
the diagnosis of SLE might be helpful and represents a
non-invasive biological marker in the follow-up of SLE
patients. When the measurement shows no such Ab,
the likelihood of severe lupus nephritis (stage IIIuIV) is
low. However, only time and practice will tell whether
these initial observations based on clinical studies are
directly of help to the clinician.
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